Histology
Adenocarcinoma
CI-CAN-00000403Explore in graph →
2,753 active trials43 approved drugs423 evidence items
Loading cancer entity…
Loading cancer entity…
Histology
CI-CAN-00000403Explore in graph →
Clinical trials
9,703 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,319)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04387500 | Sintilimab Injection Combined With Inlyta in Fumarate Hydratase- Deficient Renal Cell Carcinoma | unknown | Phase 2 | 41 | West China HospitalOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06355700 | Hepatocellular Carcinoma Liver Organoids(HELIO) | unknown | N/A | 10 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Apr 9, 2024 | clinicaltrials |
| NCT06182306 | Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)(PEAR-MET) | unknown | — | 30 | Ourotech, Inc.INDUSTRY | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06342323 | The Optimal Number of Fiducial Marker for Stereotactic Body Radiotherapy(ONFM-SBRT) | unknown | — | 57 | Peking University Third HospitalOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT05311618 | Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | unknown | Phase 1 | 71 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05626985 | Refinement and Validation of a Diagnostic Model (GAMAD) for Early Detection of Hepatocellular Carcinoma | unknown | — | 2,000 | Singlera Genomics Inc.INDUSTRY | 1 | Apr 1, 2024 | clinicaltrials |
| NCT05048524 | Peri-operative SLOG for Localized Pancreatic Cancer | unknown | Phase 2 | 64 | National Health Research Institutes, TaiwanOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06325267 | Clinical Characteristics of Primary Liver Cancer | unknown | — | 1,000 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 27, 2024 | clinicaltrials |
| NCT06328283 | The Diagnostic Efficacy of Glutamine Synthetaseand BCLAF1in Early Diagosis of Hepatocellular Carcinoma in Cirrhotic Patients | unknown | — | 90 | Sohag UniversityOTHER | 1 | Mar 25, 2024 | clinicaltrials |
| NCT06322745 | Thulium Beam Coagulation Versus Suture Renorrhaphy for Hemostasis of Tumor Bed in Laparoscopic Partial Nephrectomy | unknown | N/A | 30 | Al-Azhar UniversityOTHER | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06317298 | Fruquintinib Plus Everolimus as 2nd Line Therapy of ccRCC Patients Progressed Post IO and TKI Therapy | unknown | N/A | 36 | Peking University First HospitalOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT04354324 | Treatment Efficacy and Safety of Low-dose Radioiodine Ablation for Intermediate-risk Differentiated Thyroid Carcinoma | unknown | N/A | 254 | Zhujiang HospitalOTHER | 1 | Mar 15, 2024 | clinicaltrials |
| NCT04903873 | A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 110 | EutilexINDUSTRY | 2 | Mar 15, 2024 | clinicaltrials |
| NCT05783570 | To Evaluate the Safety, Tolerability and Preliminary Efficacy of EU307 | unknown | Phase 1 | 12 | EutilexINDUSTRY | 1 | Mar 15, 2024 | clinicaltrials |
| NCT06304766 | Open Versus Laparoscopic Ablation of Liver Malignancies(OPTIMAL) | unknown | N/A | 80 | Rigshospitalet, DenmarkOTHER | 1 | Mar 13, 2024 | clinicaltrials |
| NCT04062656 | Perioperative Immunotherapy vs. Chemo-immunotherapy in Patients With Advanced GC and AEG(IMAGINE) | unknown | Phase 2 | 21 | University Hospital, EssenOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06302881 | Differentiating Tumor-stroma Ratio in Pancreatic Ductal Adenocarcinoma | unknown | — | 207 | First Affiliated Hospital of Chongqing Medical UniversityOTHER | 0 | Mar 12, 2024 | clinicaltrials |
| NCT04605185 | Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma | unknown | Phase 1 | 18 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT05472857 | Clinical Study of CLDN18.2-targeting CAR T Cells in Advanced Solid Tumors With Positive CLDN18.2 Expression | unknown | Phase 1 | 30 | Suzhou Immunofoco Biotechnology Co., LtdINDUSTRY | 1 | Mar 6, 2024 | clinicaltrials |
| NCT04780217 | Intravenous T3011 Given as a Single Agent and in Combination With Other Therapy in Subjects With Advanced Solid Tumors | unknown | Phase 1 / Phase 2 | 42 | ImmVira Pharma Co. LtdINDUSTRY | 1 | Mar 4, 2024 | clinicaltrials |
| NCT05637788 | Artificial Intelligence and Hepatocellular Carcinoma(ARTIHCC) | unknown | — | 535 | Humanitas Clinical and Research CenterOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT06229405 | Development of Clinical Evidence for Optimal Management of Adrenal Diseases Based on Real-World Data | unknown | — | 8,200 | Seoul National University HospitalOTHER | 1 | Mar 4, 2024 | clinicaltrials |
| NCT04739670 | Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer(BELLA) | unknown | Phase 2 | 31 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT06285019 | Modified TOMOX-HAIC in Combination With Sintilimab and Bevacizumab Biosimilar for First-line Treatment of Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 65 | Fudan UniversityOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT06075849 | Phase I Study to Evaluate Safety and Anti-tumor Activity of PB101, an Anti-angiogenic Immunomodulating Agent | unknown | Phase 1 | 30 | Panolos BioscienceINDUSTRY | 1 | Feb 23, 2024 | clinicaltrials |
| NCT05178043 | GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 5 | Suzhou Kintor Pharmaceutical Inc,INDUSTRY | 1 | Feb 22, 2024 | clinicaltrials |
| NCT05591053 | Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans | unknown | N/A | 70 | Activ SurgicalINDUSTRY | 1 | Feb 21, 2024 | clinicaltrials |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | unknown | Phase 1 / Phase 2 | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Feb 21, 2024 | clinicaltrials |
| NCT03500380 | A Study of RC48-ADC Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer With or Without Liver Metastases | unknown | Phase 2 / Phase 3 | 301 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06210334 | HAIC Combine Tislelizumab and Lenvatinib in the Treatment of HCC With Type IV (Vp4) Portal Vein Tumor Thrombus (HAI-TL)(HAI-TL) | unknown | Phase 2 | 54 | Li Xiao WeiOTHER | 1 | Feb 20, 2024 | clinicaltrials |
| NCT06148155 | A Study of [68Ga]Ga-NOTA-RG2 PET Imaging in the Diagnosis of Hepatocellular Carcinoma | unknown | N/A | 20 | Huashan HospitalOTHER | 1 | Feb 16, 2024 | clinicaltrials |
| NCT03818685 | Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease(BreastImmune03) | unknown | Phase 2 | 95 | Centre Leon BerardOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05028933 | IMC001 for Clinical Research on Advanced Digestive System Malignancies | unknown | Phase 1 | 48 | Zhejiang UniversityOTHER | 1 | Feb 12, 2024 | clinicaltrials |
| NCT05842317 | Lenvatinib Plus Tislelizumab With or Without TACE in First-line Treatment of Unresectable HCC | unknown | Phase 1 / Phase 2 | 60 | Peking Union Medical College HospitalOTHER | 1 | Feb 9, 2024 | clinicaltrials |
| NCT05173298 | Predictive Biomarkers in Patients With Advanced Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab(HCC) | unknown | — | 100 | CHA UniversityOTHER | 1 | Feb 7, 2024 | clinicaltrials |
| NCT06247293 | Surgical Resection Combined With Intraperitoneal Hyperthermic Chemotherapy | unknown | — | 100 | Zhujiang HospitalOTHER | 0 | Feb 7, 2024 | clinicaltrials |
| NCT06031818 | Usability and Clinical Effectiveness of an Interpretable Deep Learning Framework for Post-Hepatectomy Liver Failure Prediction | unknown | — | 80 | Maastricht UniversityOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT06244446 | Efficacy and Safety of SBRT Combined With Atezolizumab Plus Bevacizumab vs Atezolizumab Plus Bevacizumab in Treating Unresectable Advance Hepatocellular Carcinoma. | unknown | — | 40 | Institute of Liver and Biliary Sciences, IndiaOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT04161287 | Comparison of Efficacy in SBRT of HCC ≤5 cm With or Without TACE | unknown | — | 330 | Beijing 302 HospitalOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT05526573 | Diagnostic Yeld of Ultrathin Bronchoscopy in Peripheral Pulmonary Lesions | unknown | — | 148 | Azienda Sanitaria-Universitaria Integrata di UdineOTHER | 1 | Feb 2, 2024 | clinicaltrials |
| NCT03799939 | Chimney Trial of Parastomal Hernia Prevention | unknown | N/A | 141 | University of OuluOTHER | 2 | Feb 1, 2024 | clinicaltrials |
| NCT04560894 | SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular Carcinoma(HCC) | unknown | Phase 2 / Phase 3 | 405 | Sinocelltech Ltd.INDUSTRY | 1 | Feb 1, 2024 | clinicaltrials |
| NCT05266937 | Atezolizumab Plus CArboplatin Plus Nab-paclitaxel | unknown | Phase 2 | 49 | Consorzio OncotechOTHER | 1 | Feb 1, 2024 | clinicaltrials |
| NCT04682847 | Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers | unknown | — | 40 | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)OTHER | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06233994 | A Study Evaluating the Efficacy and Safety of ZG005 in Combination With Donafenib or Bevacizumab in Patients With Advanced Hepatocellular Carcinoma | unknown | N/A | 30 | Changsha Taihe HospitalOTHER_GOV | 1 | Jan 31, 2024 | clinicaltrials |
| NCT06222944 | Anlotinib, TQB2450 (PD-L1 Inhibitor), and Albumin-bound Paclitaxel Regimens in the Treatment of GC/GEJA | unknown | Phase 2 | 90 | Peking UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | unknown | Phase 2 / Phase 3 | 62 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05711823 | Aprepitant Plus Granisetron and Dexamethasone for the Prevention of Vomiting in Patients With HAIC Therapy for HCC | unknown | Phase 3 | 300 | Guangxi Medical UniversityOTHER | 0 | Jan 23, 2024 | clinicaltrials |
| NCT05910970 | Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation(PREVENT-2) | unknown | Phase 3 | 200 | Guangxi Medical UniversityOTHER | 1 | Jan 23, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Apr 9, 2024source: clinicaltrials